RS54822B1 - Kompozicija i formulacija koja obuhvata rekombinovanu humanu iduronat-2-sulfatazu i postupak za njeno dobijanje - Google Patents

Kompozicija i formulacija koja obuhvata rekombinovanu humanu iduronat-2-sulfatazu i postupak za njeno dobijanje

Info

Publication number
RS54822B1
RS54822B1 RS20160383A RSP20160383A RS54822B1 RS 54822 B1 RS54822 B1 RS 54822B1 RS 20160383 A RS20160383 A RS 20160383A RS P20160383 A RSP20160383 A RS P20160383A RS 54822 B1 RS54822 B1 RS 54822B1
Authority
RS
Serbia
Prior art keywords
sulfatase
composition
formulation
preparation
recombinant human
Prior art date
Application number
RS20160383A
Other languages
English (en)
Inventor
Thong-Gyu Jin
Yo Kyung Chung
Sang Hoon Paik
Yoo Chang Park
Jinwook Seo
Yong Woon Choi
Jong Mun Son
Yong-Chul Kim
Original Assignee
Green Cross Corp
Medigenebio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46716009&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS54822(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Green Cross Corp, Medigenebio Corp filed Critical Green Cross Corp
Publication of RS54822B1 publication Critical patent/RS54822B1/sr
Publication of RS54822B2 publication Critical patent/RS54822B2/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Kompozicija iduronat-2-sulfataze (IDS) koja ima amino kiselinsku sekvencu SEQID NO: 1, u kojoj je cisteinski ostatak na položaju 59 u IDS amino kiselinskoj sekvenci konvertovan u formilglicin (FGly) pri molarnom odnosu od 65% ili više, poželjno pri molarnom odnosu od 75% ili više.Prijava sadrži još 13 patentnih zahteva.
RS20160383A 2011-06-24 2012-06-15 Kompozicija i formulacija koja obuhvata rekombinovanu humanu iduronat-2-sulfatazu i postupak za njeno dobijanje RS54822B2 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161500994P 2011-06-24 2011-06-24
KR1020120012718A KR101158673B1 (ko) 2011-06-24 2012-02-08 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
EP12803297.6A EP2723369B2 (en) 2011-06-24 2012-06-15 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
PCT/KR2012/004734 WO2012177020A2 (en) 2011-06-24 2012-06-15 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof

Publications (2)

Publication Number Publication Date
RS54822B1 true RS54822B1 (sr) 2016-10-31
RS54822B2 RS54822B2 (sr) 2023-09-29

Family

ID=46716009

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160383A RS54822B2 (sr) 2011-06-24 2012-06-15 Kompozicija i formulacija koja obuhvata rekombinovanu humanu iduronat-2-sulfatazu i postupak za njeno dobijanje

Country Status (28)

Country Link
US (2) US9206402B2 (sr)
EP (1) EP2723369B2 (sr)
JP (2) JP5844459B2 (sr)
KR (2) KR101158673B1 (sr)
CN (1) CN103635203B (sr)
AU (2) AU2012274215B2 (sr)
BR (1) BR112013032193A2 (sr)
CA (1) CA2839674C (sr)
CO (1) CO6862105A2 (sr)
CY (1) CY1117861T1 (sr)
DK (1) DK2723369T4 (sr)
EA (1) EA026499B1 (sr)
ES (1) ES2575377T5 (sr)
FI (1) FI2723369T4 (sr)
HK (1) HK1195731A1 (sr)
HR (1) HRP20160490T4 (sr)
HU (1) HUE027431T2 (sr)
IL (1) IL230120B (sr)
MX (1) MX341946B (sr)
MY (1) MY166647A (sr)
PE (1) PE20140734A1 (sr)
PL (1) PL2723369T5 (sr)
PT (1) PT2723369E (sr)
RS (1) RS54822B2 (sr)
SI (1) SI2723369T2 (sr)
SM (1) SMT201600194B (sr)
UA (1) UA109949C2 (sr)
WO (1) WO2012177020A2 (sr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN106153744B (zh) * 2015-03-31 2020-11-10 三生国健药业（上海）股份有限公司 融合蛋白二硫键配对分析方法
CN106153745B (zh) * 2015-03-31 2020-11-10 三生国健药业（上海）股份有限公司 抗体蛋白二硫键配对分析方法
CN106153746B (zh) * 2015-03-31 2020-11-06 三生国健药业（上海）股份有限公司 IgG2型单抗二硫键配对分析方法
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
KR20170004814A (ko) 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
DK3397270T3 (da) * 2015-12-30 2024-05-06 Green Cross Corp Sammensætninger til anvendelse i behandlingen af hunters syndrom
EP3420072A4 (en) * 2016-02-22 2019-08-28 Agency for Science, Technology and Research CELL CULTURE MEDIUM
IL307936A (en) * 2017-04-14 2023-12-01 Regenxbio Inc Treatment for mucopolysaccharidosis 2 with the help of recombinant human iduronate-2 suplatase (ids) produced by human neuron or glial cells
JP2020528756A (ja) * 2017-07-28 2020-10-01 ハンミ ファーマシューティカル カンパニー リミテッド イズロン酸−２−スルファターゼ結合体
JP2021500857A (ja) 2017-10-02 2021-01-14 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 酵素補充療法用酵素を含む融合タンパク質
KR102671857B1 (ko) 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
WO2020050947A2 (en) * 2018-09-05 2020-03-12 Sangamo Therapeutics, Inc. Enzymatic assays for quantifying therapy in subjects with mucopolysaccharidosis type i or ii
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES
CA3209611A1 (en) 2021-02-10 2022-08-18 Regenxbio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
WO2024144003A1 (ko) * 2022-12-29 2024-07-04 주식회사 녹십자 뮤코다당질 축적증에서의 안면 이형의 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
IL155588A0 (en) * 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US8227212B2 (en) * 2003-02-11 2012-07-24 Shire Human Genetic Therapies, Inc. Cell that expresses a sulfatase and a formylglycine generating enzyme
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제

Also Published As

Publication number Publication date
MX341946B (es) 2016-09-08
CN103635203A (zh) 2014-03-12
PE20140734A1 (es) 2014-07-04
WO2012177020A9 (en) 2013-02-14
JP2016056179A (ja) 2016-04-21
EP2723369A4 (en) 2014-12-24
EP2723369B1 (en) 2016-04-13
EA201490149A1 (ru) 2014-09-30
DK2723369T4 (da) 2023-07-24
US9249397B2 (en) 2016-02-02
US20140242059A1 (en) 2014-08-28
HRP20160490T1 (hr) 2016-08-12
SI2723369T2 (sl) 2023-08-31
BR112013032193A2 (pt) 2017-11-21
NZ620284A (en) 2015-11-27
HK1195731A1 (zh) 2014-11-21
ES2575377T3 (es) 2016-06-28
SI2723369T1 (sl) 2016-09-30
JP5844459B2 (ja) 2016-01-20
AU2012274215B2 (en) 2015-12-10
ES2575377T5 (es) 2023-10-26
KR20160030591A (ko) 2016-03-21
CO6862105A2 (es) 2014-02-10
JP2014520143A (ja) 2014-08-21
WO2012177020A2 (en) 2012-12-27
AU2016201487A1 (en) 2016-03-24
PL2723369T5 (pl) 2024-02-05
EA026499B1 (ru) 2017-04-28
UA109949C2 (uk) 2015-10-26
AU2016201487B2 (en) 2017-10-19
HUE027431T2 (en) 2016-09-28
JP6000432B2 (ja) 2016-09-28
IL230120B (en) 2020-09-30
CY1117861T1 (el) 2017-05-17
MY166647A (en) 2018-07-18
WO2012177020A3 (en) 2013-04-04
CN103635203B (zh) 2016-06-08
CA2839674C (en) 2018-04-24
FI2723369T4 (fi) 2023-08-31
KR101910124B1 (ko) 2018-10-19
AU2012274215A1 (en) 2014-02-20
DK2723369T3 (en) 2016-06-13
SMT201600194B (it) 2016-08-31
CA2839674A1 (en) 2012-12-27
EP2723369B2 (en) 2023-05-10
US9206402B2 (en) 2015-12-08
PL2723369T3 (pl) 2016-09-30
RS54822B2 (sr) 2023-09-29
MX2013015127A (es) 2014-06-11
PT2723369E (pt) 2016-06-03
US20150320843A1 (en) 2015-11-12
HRP20160490T4 (hr) 2023-09-15
EP2723369A2 (en) 2014-04-30
KR101158673B1 (ko) 2012-07-03

Similar Documents

Publication Publication Date Title
RS54822B1 (sr) Kompozicija i formulacija koja obuhvata rekombinovanu humanu iduronat-2-sulfatazu i postupak za njeno dobijanje
NZ601374A (en) Stabilized antibody-containing liquid formulations
RS53559B1 (sr) Formulacije insulina sa dugotrajnim dejstvom
BR112014009146A8 (pt) formulações de etanercepte estabilizadas com aminoácidos
BR112015022095A8 (pt) composição farmacêutica, método de fabricação, composição eutética e uso de composições contendo hcl ciclobenzabrina e manitol
MY157021A (en) Oral care product and methods of use thereof
GT201300295A (es) "composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales"
MY161557A (en) Oral care product and methods of use and manufacture thereof
UA109122C2 (uk) Синергічна гербіцидна композиція, яка містить амінопіралід і 2,4-дихлорфеноксіоцтову кислоту
BR112012009487A2 (pt) formulações de espessante estáveis
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
GB2502716A (en) Fluorocarbon-linked peptide formulation
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
IL231421A (en) Lupane and its similar compounds are preserved in position 3ß by carboxy-alkyl-carbonyl-oxy and position 17- by (alkyl-conserved) amino, and also anti-HIV drug preparations containing them
UA113540C2 (xx) Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду
MY167069A (en) Antigen peptide and use thereof
IN2015DN01221A (sr)
UA114082C2 (xx) Спосіб одержання водорозчинних селеноглікопротеїнів та композиція, що їх містить
EA201300947A1 (ru) Композиция для повышения устойчивости суставов и/или позной устойчивости
AR093717A1 (es) Composiciones y metodos para el tratamiento de la caries dental
BR112015005876A2 (pt) partículas derivadas de ácido propiônico com baixo ponto de fusão para uso em formas de dosagem oral
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
MX2016002714A (es) Composicion y metodo para tropicalizar chocolate.